 |
JNJ
Johnson and Johnson $JNJ Not Moving. Kickback Schemes or Legitimate Marketing?: http://bit.ly/bpapAn
JNJ
Johnson and Johnson $JNJ Not Moving. Kickback Schemes or Legitimate Marketing?: http://bit.ly/dmAJOB
JNJ
Johnson and Johnson $JNJ Not Moving. With better handling Toyota can get its brand back on track: http://bit.ly/aI3ykw
JNJ
Johnson and Johnson $JNJ Not Moving. Kickback Schemes or Legitimate Marketing?: http://bit.ly/9eHyeE
JNJ
Congratulations to $JNJ CFO Dominic Caruso, voted as a 1st Place CFO by sell-side analystst - http://bit.ly/aUuhYU (via @irwebreport)
JNJ
Andrew Jones of E&Y points to $JNJ's Stelara & Allos' ($ALTH) Folotyn as 2009's novel drug approvals - Nature Reviews http://bit.ly/
JNJ
Thank heavens I didn't buy a Matrix in '08! Wow. It's no longer fair to compare $TM to $JNJ and Tylenol. This is a full-blown PR nightmare.
JNJ
Johnson and Johnson $JNJ Not Moving. ZACKS ANALYST BLOG HIGHLIGHTS: MASTERCARD INCORPORATED, BROA: http://bit.ly/cWdoq7
JNJ
Johnson and Johnson $JNJ Not Moving. Guvera Limited Launches Beta In Australia With Huge Success,: http://bit.ly/cEPf4n
JNJ
the Artificial Pancreas Project, $8 million partnership with Animas to develop a first-generation system http://bit.ly/94OirB $JNJ
JNJ
RT @jessefelder Toyota: How to Kill One of the Most Powerful Brands in the World http://bit.ly/deCgJ7 $TM $JNJ
JNJ
Toyota: How to Kill One of the Most Powerful Brands in the World http://bit.ly/deCgJ7 $TM $JNJ
JNJ
Stocks Going Ex Dividend 3rd Week of Feb http://bit.ly/9q9ASo $JNJ $BOH $HSY
JNJ
Johnson and Johnson $JNJ Not Moving. Market Focus with Tom Hudson: http://bit.ly/cr7w62
JNJ
Johnson and Johnson $JNJ Not Moving. Market Focus with Tom Hudson: http://bit.ly/9mz5eF
JNJ
.@mommadona My core Trading Portfolio consists of $MMM, $WAG, $TJX, $T, $CHD, $MCD, $JNJ, and $SYY and 14% cash. $$
JNJ
Johnson and Johnson $JNJ Dropped Over Half A Percent. Downturn presents new lease of life for Indian drug firms: http://bit.ly/dgLV52
JNJ
Johnson and Johnson $JNJ Dropped Over Half A Percent. Downturn presents new lease of life for Indian drug firms: http://bit.ly/9Jb4Ni
JNJ
Johnson and Johnson $JNJ Went Up Over 1%. Unilever, Diageo and J&J among winners in awards for new: http://bit.ly/bzJ6BB
JNJ
Unusual Movement: $DIS( Vol 38%,S1,R1,3dLow,2dHihg) $JNJ( Vol 59%,S1,R2,3dLow,2dHigh) $MMM( Vol 61%,S1,R1,3dLow,2dHigh)
JNJ
CAPS Members Bullish on $WU Also Bullish on $GE and $JNJ http://www.urltwit.com//nx
JNJ
CAPS Members Bullish on $WU Also Bullish on $GE and $JNJ http://www.urltwit.com//nx
JNJ
http://bit.ly/bH0rP6 $BSX $JNJ Boston Scientific to Pay $1.7 Billion to Settle Patent Suits
JNJ
$BSX v/s $JNJ - Huge Pay day for Johnson & Johnson! Boston Scientific to pay JNJ $1.73B in settlement - http://bit.ly/cujvL9 $$
JNJ
Johnson and Johnson $JNJ A Little Up. Watson inks generics deal with Indian pharma; J&J to get: http://bit.ly/aJolMV
JNJ
Johnson and Johnson $JNJ Now Trading. Boston Scientific Corporation (BSX) to Pay Johnson & Joh: http://bit.ly/brjYio
JNJ
Boston Sci Pays J&J $1.7B to End Stent Patent Dispute - Stocks To Watch Today - Barrons.com $BSX $JNJ http://bit.ly/cru4ee
JNJ
Reuters: Boston Scientific to pay J&J $1.73B to settle stent patent fights. $BSX $JNJ
JNJ
Albert-Culver Off on Q1 Revenue Miss - Stocks To Watch Today - Barrons.com $ACV $BARE $REV $JNJ $CL $PG http://bit.ly/bol8nE
Johnson & Johnson - JNJ Insiders
JNJComm, 3261 follower(s), 1421 friend(s)Marc Monseau, Company
Description: I work at Johnson & Johnson, and will Tweet about topics that I'm familiar with and that I write about on our blog, JNJBTW.
URL: http://www.jnjbtw.com
Johnson & Johnson - JNJ information
Johnson & Johnson engages in the research and development, manufacture, and sale of various products in the health care field worldwide. Its Consumer segment provides products used in baby care, skin care, oral care, wound care, and women?s health care fields, as well as nutritional and over-the-counter pharmaceutical products under JOHNSON?S, AVEENO, CLEAN & CLEAR, NEUTROGENA, RoC, LUBRIDERM, LISTERINE, REACH, CAREFREE, STAYFREE, SPLENDA, TYLENOL, SUDAFED, ZYRTEC, MOTRIN IB, and PEPCID AC names. The company?s Pharmaceutical segment offers products in various therapeutic areas, such as anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology, and virology. Its products include REMICADE, a biologic to treat Crohn?s disease, ankylosing spondylitis, psoriasis, psoriatic arthritis, ulcerative colitis, and used to treat rheumatoid arthritis; TOPAMAX, for adjunctive and monotherapy use in epilepsy, as well as for treating migraines; PROCRIT that stimulates red blood cell production; RISPERDAL oral, a medication to treat the symptoms of schizophrenia, bipolar mania, and irritability associated with autistic behavior in indicated patients; RISPERDAL CONSTA, an injectable, and INVEGATM Extended-Release tablets to treat schizophrenia; LEVAQUIN and FLOXIN, anti-infective products; CONCERTA, a product for treating attention deficit hyperactivity disorder; ACIPHEX/PARIET, a proton pump inhibitor; and DURAGESIC/Fentanyl Transdermal, a treatment for chronic pain. Johnson & Johnson?s Medical Devices and Diagnostics segment offers circulatory disease management, orthopaedic joint reconstruction and spinal care and sports medicine, surgical care and women?s health, minimally invasive surgical, blood glucose monitoring and insulin delivery, and diagnostic products, as well as disposable contact lenses. The company was founded in 1886 and is based in New Brunswick, New Jersey....
www.jnj.com
Founded in 1886
JOHNSON & JOHNSON (JNJ:NYSE)
LAST $63.93 USD
CHANGE TODAY -0.36 -0.56%
VOLUME 6.3M
As of 2:39 PM 03/11/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of JOHNSON & JOHNSON (JNJ)
|
OPEN
$64.15
|
PREVIOUS CLOSE
$64.29
|
|
|
DAY HIGH
$64.21
|
DAY LOW
$63.60
|
|
|
52 WEEK HIGH
01/20/10 - $65.95
|
52 WEEK LOW
03/12/09 - $47.33
|
|
|
MARKET CAP
175.9B
|
AVERAGE VOLUME 10 D
11.7M
|
|
|
EPS TTM
$4.63
|
SHARES OUTSTANDING
2.8B
|
|
|
EX-DATE
02/19/10
|
P/E TTM
13.8x
|
|
|
DIVIDEND
$1.96
|
DIVIDEND YIELD
3.07%
|
|
| K = Thousands M = Millions B = Billions | ||
related news
*Midday Glance: Pharmaceuticals companies
AP Digital - 03/11/2010 1:04 PM ET
Midday Glance: Medical Devices companies
AP Digital - 03/11/2010 1:04 PM ET
Basilea asks regulators to reconsider antibiotic
AP Digital - 03/11/2010 12:29 PM ET
*Early Glance: Pharmaceuticals companies
AP Digital - 03/11/2010 10:49 AM ET
Early Glance: Medical Devices companies
AP Digital - 03/11/2010 10:49 AM ET
Key developments for JOHNSON & JOHNSON (JNJ)
Johnson & Johnson Ends Deal with Basilea Pharmaceutica
02/19/2010
A highly touted drug for dangerous MRSA skin infections being developed by Johnson & Johnson and Swiss partner Basilea Pharmaceutica AG is rejected by European regulators after the FDA did the same, and J&J immediately ends the partnership.
Johnson & Johnson Presents at 8th Cold Chain Management & Temperature Control Summit, Feb-25-2010
02/16/2010
Johnson & Johnson Presents at 8th Cold Chain Management & Temperature Control Summit, Feb-25-2010. Venue: Westin Harbour Castle, 1 Harbour Square, Toronto, Ontario M5J 1A6, Ontario, Canada. Speakers: Hashim Ayyaril, Manager, Product Logistics, Ortho Clinical Diagnostics.
Johnson & Johnson Presents at Diversity & Inclusion Leadership and Management Seminars in 2010, Feb-17-2010 through Feb-18-2010
02/11/2010
Johnson & Johnson Presents at Diversity & Inclusion Leadership and Management Seminars in 2010, Feb-17-2010 through Feb-18-2010. Venue: InterContinental The Barclay New York, New York, New York, United States. Speakers: Arisa Batista Cunningham, Vice President, Global Diversity, Medical Devices and Diagnostics Group.
JNJ Competitors
| Company | Last | Change |
| Archer-Daniels-Midland Co | $29.50 USD | -0.74 |
| Nokia OYJ | €10.59 EUR | -0.08 |
| Pfizer Inc | $17.19 USD | +0.04 |
| Toshiba Corp | ¥440.00 JPY | +1.00 |
| Unilever NV | €22.61 EUR | -0.10 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | JNJ | Industry Range |
| Price/Earnings | 14.6x |
|
| Price/Sales | 2.9x |
|
| Price/Book | 3.5x |
|
| Price/Cash Flow | 14.4x |
|
| TEV/Sales | 2.3x |
|
|
JNJ |
||
|
JNJ transactions
| Type Date |
Target |
|
Merger/Acquisition
October 7, 2009 |
Johnson & Johnson, JONTEX |
Johnson & Johnson - JNJ news
Pharmaceutical group spent $6.3M lobbying in Q4
2010-03-11 02:11:58
Quote: The group's members include drug giants Pfizer Inc., Merck & Co., Johnson & Johnson and more than two dozen other U.S. and foreign companies.PhRMA lobbied on multiple aspects of the health care overhaul, including several bills to allow approval of generic versions of expensive biologic drugs -- an idea that most traditional pharmaceutical companies support as a new area where they could make money. It is generally opposed by the biotech firms that initially develop such drugs.National Institute...Read article
Johnson & Johnson executive Renee Selman joins Catalina Marketing
2010-03-10 07:26:21
Quote: Read article
ACUVUE(R) Brand Contact Lenses Celebrates Spring With a Chance to Win a $10,000 Shopping Spree
2010-03-10 07:26:19
Quote: JACKSONVILLE, Fla., March 10 /PRNewswire-FirstCall/ -- VISTAKON®, Division of Johnson & Johnson Vision Care, Inc., and makers of ACUVUE® Brand Contact Lenses, today announced the ACUVUE® SEE SPRING Sweepstakes. Now through April 30thwww.trycomfort.com to enter the ACUVUE® SEE SPRING Sweepstakes for a chance to win the grand prize of $10,000, as well as a $100 VISA® gift card awarded daily throughout the sweeps entry period. Visitors also can download a Free* Trial Pair Certificate...Read article
China Still Offers Opportunity of a Lifetime
2010-03-09 01:11:24
Quote: As China accepts more foreign influence and grows wealthier, demand for American products should increase, leading to gains for Apple" PRIMARY="NO"/>, Microsoft" PRIMARY="NO"/>, Wal-Mart" PRIMARY="NO"/> and Johnson & Johnson" PRIMARY="NO"/>. Apple's sales to Asia increased from $599 million in 2004 to $3.3 billion in 2009. Similarly, Google's" PRIMARY="NO"/> revenue from what it calls the "rest of the world," i.e. emerging-market countries, increased from 21% of the total in 2004 to 40% last ear...Read article
What to Expect From Health-Care ETFs
2010-03-09 01:11:21
Keywords: health,care,etf,analysts,,BUSINESS & MARKETS ,VHT,PTJ,WLP,HUM,UNH
Quote: Read article
Sanofi's Cancer Drug May Set New Standard
2010-03-04 09:10:20
Keywords: Financial, News, Stock, Market, Headlines, Investments, Quotes, Trading, TheStreet.com, Adam Feuerstein ,Biotech
Quote: BOSTON (TheStreet) -- Sanofi-Aventis'(SNY Quote) success with its new prostate cancer drug could present challenges for competing late-stage drugs from Medivation(MDVN Quote) and Johnson & Johnson(JNJ Quote).Dendreon'sDNDN Quote) prostate cancer vaccine Provenge should not be affected, however.Sanofi's cabazitaxel, an experimental drug, extended significantly the survival of men who failed previous chemotherapy treatment for advanced prostate cancer, according to results from a phase III study d...Read article
JOHNSON & JOHNSON Files SEC form 10-K, Annual Report
2010-03-02 01:52:48
Quote: JOHNSON & JOHNSONRequest a Trial to NEW EDGAR Online Pro
Form
10-K for
JOHNSON & JOHNSON
1-Mar-2010Annual ReportPrivacy PolicyAbout Our AdsTerms of ServiceCopyright/IP PolicySend FeedbackSEC
Filing data and information provided by EDGAR Online,
Inc.
(1-800-416-6651). All information provided "as is"
for informational purposes
only, not intended for trading purposes or advice.
Neither Yahoo! nor any of
independent providers is liable for any informational
errors, incompleteness,
or delays, or for...Read article
Buffet's Next Act
2010-03-01 06:20:43
Keywords: Warren Buffett, Investing, Recession, Economy, Charlie Munger, Value Investing, Stock Markets
Quote: Read article
UPDATE - Bayer sets modest target for 2010 core profit
2010-02-26 04:10:55
Keywords: Germany,Western Europe,Europe,Chemicals,Pharmaceuticals (sub-industry),Health and medicine,Corporate Results,Corporate Results Forecasts,United States of America,Regulation and enforcement,Central and Eastern Europe,General News,Nature Society and Science
Quote: Read article
UPDATE - Basilea strikes licensing deal with Astellas
2010-02-24 03:48:59
Keywords: Western Europe,Europe,Switzerland,Pharmaceuticals (sub-industry),Biotechnology,Hot stocks,Equities,Mergers and Acquisitions (including Changes of Ownership),Japan,Asia,United States of America,Central and Eastern Europe,Healthcare,Economic news, EC, busin
Quote: Read article